Emotional Disclosure in HIV
Efficacy of an Emotional Disclosure Intervention in HIV
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Florida
-
Coral Gables, Florida, United States, 33124-2070
- University of Miami Dept. of Psychology & Behavioral Medicine
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria
- 18-65 years of age inclusive
- At least 8 years of formal education
- Literate
- Fluent in English
All of the following three must apply:
- No active Category C HIV AIDS-defining symptoms
- CD4 T-lymphocyte count between 150-499
- Viral load >1000
Exclusion Criteria
- Less than 8 years formal education
- Illiterate or non-English speaking
- Active systemic diseases that would interfere with participation
- Current alcohol or substance dependence
- Planned change in HIV medication in the next 6 months, or recent change in past 2 months
- Introduction of antidepressant medication within 30 days of study start
- Current psychological counseling, cognitive behavior therapy, support group or other psychological therapy, or plans to start any of the above
- Diagnosis of PTSD or major depression
- Unable to attend at least 4 treatment sessions
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Trauma writing
Four sessions of writing about traumatic experiences.
|
|
|
Sham Comparator: Writing about daily events
Four sessions of writing about their daily experiences.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Decrease in psychological distress
Time Frame: 1 year
|
1 year
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Increase in CD4 T-lymphocytes
Time Frame: 1 year
|
1 year
|
|
Decrease in the number of HIV symptoms
Time Frame: 1 year
|
1 year
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Investigators
Investigators
- Principal Investigator: Gail Ironson, MD, University of Miami Dept. of Psychology & Behavioral Medicine
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Estimate)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- 20020511
- R01AT002035 (U.S. NIH Grant/Contract)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.